<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610215</url>
  </required_header>
  <id_info>
    <org_study_id>2022-1736</org_study_id>
    <nct_id>NCT05610215</nct_id>
  </id_info>
  <brief_title>Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy</brief_title>
  <official_title>Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to compare the rhythm control effect in hypertrophic&#xD;
      non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant&#xD;
      catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The&#xD;
      study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control&#xD;
      effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with&#xD;
      hypertrophic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, 66 eligible admissions will be recruited in 2 centers. Eligible&#xD;
      participants will be randomly divided (1:1) into either hybrid or catheter ablation arms,&#xD;
      looking for a primary outcome of 1-year freedom from atrial arrhythmias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from documented atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>freedom from documented AF episodes &gt;30 seconds by 72-hour monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>death by any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular related mortality</measure>
    <time_frame>12 months</time_frame>
    <description>death that related to cardiogenic causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Any stroke or TIA diagnosed in the clinical record after the completion of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periferal arterial embolism</measure>
    <time_frame>12 months</time_frame>
    <description>Periferal arterial embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause rehospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Rehospitalized by any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure related rehospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Rehospitalized by the cause of heart failure episode</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardiomyopathy, Hypertrophic</condition>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>hybrid ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>catheter ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive catheter endocardial ablation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hybrid ablation</intervention_name>
    <description>simultaneous thoracoscopic epicardial and catheter endocardial ablation</description>
    <arm_group_label>hybrid ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheter ablation</intervention_name>
    <description>catheter endocardial ablation</description>
    <arm_group_label>catheter ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients' age is ≥18 y&#xD;
&#xD;
          2. Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment&#xD;
             thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm&#xD;
             in genetical positive ones-as measured by any imaging technique (echocardiography,&#xD;
             cardiac magnetic resonance imaging or computed tomography)-that is not explained&#xD;
             solely by loading conditions)&#xD;
&#xD;
          3. Non-obstructed left ventricular outflow obstruction with peak gradients &lt;30mmHg&#xD;
&#xD;
          4. Concomitant with persistent atrial fibrillation (7 days&lt;sustained episode lasting&lt;3&#xD;
             years) with drug-refractory symptoms.&#xD;
&#xD;
          5. Be able to understand the contents of the trial, and provide written informed consent&#xD;
             to participate in this investigation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with left atrial size &gt;60 mm (2-dimensional echocardiography, parasternal&#xD;
             long-axis view)&#xD;
&#xD;
          2. Contraindicated to systemic anticoagulation&#xD;
&#xD;
          3. Left ventricular ejection fraction ≤40%&#xD;
&#xD;
          4. Concomitant with left atrium or left atrial appendage emboli&#xD;
&#xD;
          5. Concomitant with severe mitral or tricuspid regurgitation&#xD;
&#xD;
          6. Concomitant with coronary artery disease or valvular disease that needs open heart&#xD;
             surgeries&#xD;
&#xD;
          7. Ischaemic stroke within 2 months&#xD;
&#xD;
          8. Previous ablation history&#xD;
&#xD;
          9. Uncontrolled hyper/hypothyroidism&#xD;
&#xD;
         10. End-staged kidney failure&#xD;
&#xD;
         11. Concomitantly involved in other trials&#xD;
&#xD;
         12. Pregnant or breastfeeding, or women of childbearing age not using a reliable&#xD;
             contraceptive method&#xD;
&#xD;
         13. Concomitant with bacteremia or at an active phase of infection&#xD;
&#xD;
         14. Anatomically not suitable for thoracoscopic surgery(history of chest surgery or&#xD;
             radiotherapy, etc.)&#xD;
&#xD;
         15. Unwilling or unable to comply with all peri-ablation and follow-up requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zheng, MD.PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD.PhD</last_name>
    <phone>+86-010-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yajie Tang, MD.PhD</last_name>
    <phone>+8618813019554</phone>
    <email>tangyajietangyajie@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhe Zheng, MD,PhD</last_name>
      <phone>+86-010-88396051</phone>
      <email>zhengzhe@fuwai.com</email>
    </contact>
    <contact_backup>
      <last_name>Yajie Tang, MD,PhD</last_name>
      <phone>+8618813019554</phone>
      <email>tangyajietangyajie@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>February 9, 2023</last_update_submitted>
  <last_update_submitted_qc>February 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

